People with Parkinson’s disease who are given deep brain stimulation (DBS) tend to have more stable long-term life quality and motor function than do patients treated with medications only, according to a new study. Deep brain stimulation, called DBS for short, is a surgical treatment for Parkinson’s disease…
News
The first patient has been dosed, and the observation period completed, in a clinical trial in China that’s testing iRegene Therapeutics’ NouvNeu001 cell therapy for moderate to advanced Parkinson’s disease. The Phase 1/2 clinical trial (NCT06167681) started in early January at Beijing Hospital, following a green light from the…
People with epilepsy are at more than double the risk of developing Parkinson’s disease than people without epilepsy, but a cause-and-effect relationship has yet to be established, according to a large study by researchers in South Korea. “To the best of our knowledge, there are three case-control studies ……
The virus that causes COVID-19 is able to infect dopamine-producing brain cells and trigger a specific pattern of dysfunction that has been linked with the development of Parkinson’s disease, a study reports. “Given our findings, we posit that over the coming years, there is a need to closely monitor…
Vaxxinity has entered into a research collaboration with the University of Florida to advance the development of vaccines for neurodegenerative diseases, including Parkinson’s disease. Funded by a grant from the state of Florida, the partnership aims to advance Vaxxinity’s lead immunotherapy candidates, designed to prevent and manage…
A new dual-target, adaptive deep brain stimulation (DBS) protocol may offer more clinical benefits for patients than does traditional DBS for Parkinson’s disease, according to newly published data from a small clinical trial. DBS surgery — in which a small device is implanted in the brain to deliver…
Topline data from a Phase 3 clinical trial of buntanetap in early-stage Parkinson’s disease patients is expected soon, according to Annovis Bio, the therapy’s developer. Initially planned for the end of January, ongoing analysis to ensure “clean data” that are accurate and reliable was cited as the reason…
University Hospitals (UH) healthcare system in Cleveland, Ohio, has been named one of four new sites for a Global Parkinson’s Genetics Program (GP2) study that seeks to better understand Parkinson’s disease in Black people, with a focus on the disorder’s genetic basis. Improved knowledge of genetic variants…
Risvodetinib, an experimental therapy that Inhibikase Therapeutics is developing for Parkinson’s disease, was well tolerated both by healthy volunteers and Parkinson’s patients in a Phase 1 clinical trial. That’s according to the full results from the Inhibikase-funded work, detailed in a study titled “A Phase I, Randomized,…
Researchers from a university in Scotland were among the contributors to recent World Health Organization (WHO) guidelines outlining the most essential interventions in rehabilitation for 20 health conditions — including Parkinson’s disease — with high prevalence and elevated levels of associated disability. The WHO’s “Package of Interventions for Rehabilitation”…
Recent Posts
- New $2M MJFF grant backs Parkinson’s walking study at Boston University
- My fear of falling has gotten worse since my Parkinson’s diagnosis
- New compound targets mitochondrial damage in Parkinson’s models
- Environmental factors may impact Parkinson’s disease risk: Dutch study
- Finding solutions for REM sleep behavior disorder with Parkinson’s